Regencell Net Working Capital vs Accounts Payable Analysis
| RGC Stock | USD 5.87 0.22 3.89% |
Regencell Bioscience financial indicator trend analysis is much more than just breaking down Regencell Bioscience prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regencell Bioscience is a good investment. Please check the relationship between Regencell Bioscience Net Working Capital and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Net Working Capital vs Accounts Payable
Net Working Capital vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regencell Bioscience Net Working Capital account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Regencell Bioscience's Net Working Capital and Accounts Payable is 0.41. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Regencell Bioscience Holdings, assuming nothing else is changed. The correlation between historical values of Regencell Bioscience's Net Working Capital and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Regencell Bioscience Holdings are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Working Capital i.e., Regencell Bioscience's Net Working Capital and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.41 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Net Working Capital
Accounts Payable
An accounting item on the balance sheet that represents Regencell Bioscience obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Regencell Bioscience are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Regencell Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regencell Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. At present, Regencell Bioscience's Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 8.06, whereas Selling General Administrative is forecasted to decline to about 3.5 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 7.6M | 6.3M | 4.0M | 3.8M | Cost Of Revenue | 604.4K | 769.7K | 745.6K | 708.3K |
Regencell Bioscience fundamental ratios Correlations
Click cells to compare fundamentals
Regencell Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regencell Bioscience fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 514.0K | 340.1K | 18.0M | 12.6M | 8.4M | 8.0M | |
| Short Long Term Debt Total | 3.1M | 3.7M | 771.3K | 463.7K | 85.7K | 81.5K | |
| Total Current Liabilities | 3.2M | 4.3M | 577.8K | 606.9K | 193.6K | 183.9K | |
| Total Stockholder Equity | (2.7M) | (4.0M) | 17.1M | 12.0M | 8.2M | 8.6M | |
| Net Debt | 2.7M | 3.6M | (5.6M) | (1.1M) | (2.9M) | (2.7M) | |
| Retained Earnings | (2.7M) | (4.0M) | (11.4M) | (17.3M) | (21.6M) | (20.5M) | |
| Cash | 387.0K | 59.4K | 6.4M | 1.6M | 3.0M | 2.8M | |
| Non Current Assets Total | 127.0K | 273.3K | 1.6M | 1.0M | 324.2K | 308.0K | |
| Cash And Short Term Investments | 387.0K | 59.4K | 16.4M | 11.6M | 8.0M | 7.6M | |
| Liabilities And Stockholders Equity | 514.0K | 340.1K | 18.0M | 12.6M | 8.4M | 8.0M | |
| Non Current Liabilities Total | 3.1M | 3.7M | 360.3K | 25.4K | 25.9K | 24.6K | |
| Total Liab | 3.2M | 4.3M | 938.0K | 632.3K | 219.5K | 208.5K | |
| Total Current Assets | 387.0K | 66.8K | 16.4M | 11.6M | 8.1M | 7.7M | |
| Short Term Debt | 3.1M | 3.7M | 411.0K | 438.3K | 59.8K | 56.8K | |
| Net Invested Capital | 419.0K | (315.7K) | 17.1M | 12.0M | 8.2M | 6.9M | |
| Net Working Capital | (2.8M) | (4.3M) | 15.9M | 11.0M | 7.9M | 4.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.